XOMA Royalty to Acquire LAVA Therapeutics in a Deal Worth Up to $1.24 Per Share Plus Contingent Value Rights

XOMA Royalty Corporation (NASDAQ: XOMA) and LAVA Therapeutics N.V. (NASDAQ: LVTX) have entered into a definitive share purchase agreement, setting the stage for XOMA Royalty to acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR). This strategic acquisition underscores the potential of LAVA's gamma delta bispecific antibodies in revolutionizing cancer treatment, offering a promising avenue for patient care advancements.

The transaction, expected to close in the fourth quarter of 2025, is subject to customary closing conditions, including the tender of at least 80% of LAVA's outstanding shares. The deal not only highlights the value of LAVA's innovative Gammabody® platform but also reflects XOMA Royalty's commitment to fostering biotech innovations by acquiring future economics associated with therapeutic candidates. For more details on XOMA Royalty's portfolio, visit https://www.xoma.com.

LAVA's Board of Directors has unanimously approved the purchase agreement, recommending shareholders to support the offer. This acquisition is poised to streamline LAVA's operations, including the discontinuation of its Phase 1 clinical trial of LAVA-1266, as part of a strategic shift towards maximizing shareholder value and focusing on partnered programs. Learn more about LAVA Therapeutics at https://www.lavatherapeutics.com.

The collaboration between XOMA Royalty and LAVA Therapeutics represents a significant milestone in the biotech industry, combining XOMA's expertise in royalty aggregation with LAVA's innovative approach to cancer treatment. This deal not only promises to deliver immediate financial benefits to shareholders but also holds the potential to accelerate the development of groundbreaking therapies for patients worldwide.